Loading
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Latest quote
$4.35
$0.00 · 0.00%
After-hours
$4.35
$0.00 · 0.00%
Sep 16, 7:30 PM ET
Regular session · ET · Market data may be delayed.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Day range
Current $4.35
52-week range
Current $4.35
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
37
Expensive
Sentiment
41
Mixed
Risk
54
Elevated Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Day range
Current $4.35
52-week range
Current $4.35
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM12.54M0.02%79.89B USD0.19%$283.92-0.43%
Vanguard Morningstar Total Stock Market ETFVTI10.42M0.00%2.3T USD0.03%$371.26-0.42%
Vanguard Extended Market ETFVXF6.12M0.01%95.4B USD0.05%$234.39-0.32%
iShares Russell 2000 Value ETFIWN4.41M0.03%14.31B USD0.24%$215.86-0.84%
iShares Biotechnology ETFIBB3.96M0.04%10.45B USD0.44%$202.4+0.20%
Vanguard Russell 2000 ETFVTWO2.77M0.02%18B USD0.06%$115.07-0.43%
Schwab U.S. Small-Cap ETFSCHA2.42M0.01%22.03B USD0.03%$33.06-0.29%
iShares Micro-Cap ETFIWC1.62M0.11%1.44B USD0.60%$187.74-0.36%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
